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Background: Cervical cancer is the greater cause of cancer death in women in many developing countries.
Persistent infection with human papilloma virus (HPV), primarily high risk types 16 and 18, is recognized as a causal
and essential factor for the development of cervical cancer. We aimed to determine the distribution of high-risk
HPV genotypes in archival biopsies with cervical carcinoma in patients from Mazandaran Province, Northern Iran.
Methods: A total of 98 paraffin-embedded cervical samples consisted of 63 Squamous Cell Carcinomas (SCC),
4 Adenocarcinomas, 19 Cervical Interaepithelial Neoplasia grade I (CIN-I), 4 CIN-II and 8 CIN-III diagnosed during
2009–2011, were selected to perform high risk HPV genotyping using AmpliSens(R) HPV HCR DNA genotyping kit.
The prevalence of HPV infections was assessed in low and high grade cervical lesions by age.
Results: Of the 98 cervical samples analysed by DNA PCR, 78 (79.59%) were positive for HPV DNA. HPV was
detected in the 52 of SCC, 4 of Adenocarcinomas, 14 of CIN-I, 4 of CIN-II, and 4 of CIN-III for HPV. From the 78 HPV
positive samples, 23 (29.5%) samples were positive for HPV type 16, 32 (41%) were positive for HPV 18, 19 (24.4%)
were positive for HPV 45, and 4 (5.1%) of cervical specimens were positive for HPV 39.
Conclusions: This study provides valuable baseline data for future assessment of the impact of current prophylactic
vaccination programs that is protective against the two most common oncogenic types of HPV found in cervical
cancer, HPV-16 and HPV-18, but not against other high-risk mucosal HPVs, 39 and 45, reported in this population.
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Cervical cancer is one of the most common types of
cancer affecting women worldwide with over 500,000
new cases estimated and over 250,000 deaths each year.
The greatest burden of disease is in developing coun-
tries, but in spite of better screening and surveillance
cervical cancer is still a significant burden also in
developed world [1-3]. The risk of cervical cancer has
increased in parallel with the incidence of certain geno-
types of human Papillomavirus (HPV). Therefore, the
presence of these genotypes indicates a significant risk
factor for the development of cervical cancer [4-7]. HPVs* Correspondence: H.ashrafi@kingston.ac.uk
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distribution, and reproduction in any mediuminfect cutaneous and mucosal epithelial cells of the ano-
genital tract, which can lead to a variety of diseases with a
range of severities. The mildest form of HPV disease is low
grade intraepithelial neoplasia (CIN-I). These lesions can
persist and progress to high grade disease (CIN-III) and in-
vasive cervical cancer [8,9]. HPVs are also found in cancers
of the tonsils, anus, penis and cancer of neck [10,11].
High-risk HPV 16 and 18 are found with the highest
frequencies in cervical cancer and account for approxi-
mately two thirds of all cervical carcinomas worldwide
[12,13], with HPV-16 occurring most frequently [14]. It
has been demonstrated that the presence of even min-
imal amounts of HPV DNA is associated with an in-
creased risk in the development of cervical cancer [15].
Considering the broad interest in HPV vaccines, it is
very important to verify the prevalence of the variousntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Despite the medical importance and the high incidence
rate of cervical cancer, there is lack of information on
the incidence of the HPV genotypes and the provincial
differences in their distribution in Iranian population.
This study was designed to determine and analyse the
distribution of high risk HPV genotypes present in
archival biopsies of cervical tumor tissue of patients
from Mazandaran province, Northern Iran.
Methods
Cervical sample collection
This cross-sectional study, took place during 2009–2011
by approval of the Scientific Ethics Committee of the
Mazandaran University of Medical Sciences, Sari. A total
of 98 formalin-fixed and paraffin-embedded cervical
tissue fragments were retrieved from patients in attend-
ance at Imam khomini Hospital Infections Disease
Center, Mazandaran province, Northern Iran. Serial sec-
tions (4-7 μm thick) were cut from each specimen. Sep-
arate disposable items such as gloves, feather blades and
tubes were used to minimise any cross-contamination
between samples. The first and last sections were used
for histopathological evaluation and intermediate sec-
tions were transferred into sterile micro-tube for HPV
DNA detection. Additional information was obtained
from each patient and collected by means of a question-
naire (age and suspected sources of infection/high-risk
sexual relation, for example).
DNA extraction and HPV DNA detection
Sections of paraffin embedded samples in each tube
went through deparaffinization with xylene, and rehydra-
tion in graded ethanol. Genomic DNAs from tissue sec-
tion were isolated using the AccuPrepW Genomic DNA
Extraction Kit (Bioneer Corporation, Korea) according
to the manufacturer’s guidelines. HPV genotyping was
performed using the HPV- HCR Genotype-Eph kit
(AmpliSens(R), Russia). The kit is based on simultaneous
amplifying in a one tube (multiplex-PCR) of four types
of HPV DNA and allows the user to detect infections
and co-infections of high risk HPV genotypes; HPV-16,Table 1 HPV genotype distribution in women with cervical ab
Pathological
status
HPV ge
16 18
SCC 17 (32.69%) 18 (34.62%)
Adenocarcinomas 2 (50%) 2 (50%)
CIN1 4 (28.58%) 8 (57.14%)
CIN2 - 4 (100%)
CIN3 - -
Total 23 (29.49%) 32 (41.03%)31, 33, 35, HPV-18, 39, 45, 59 and HPV-52, 56, 58, 66.
PCR amplification for detection of HPV twelve types
DNA were run in three tubes. HPV-positive and nega-
tive samples were included for every sample run.
To determine HPV genotypes the amplified PCR
products were run in 1.5% agarose gel stained by eth-
idium bromide. Since all amplified products had differ-
ent length, genotypes of the virus were analysed by
electrophoresis and visualized by an ultraviolet light
trans-illuminator. Bands of appropriate size were identi-
fied by comparison with DNA molecular weight markers
which are a set of known DNA fragments.
The adequacy of the DNA in each specimen for PCR
amplification was determined by the detection of the β-
globin gene.
Results
The results of the 98 patients with an abnormal cervical
biopsy diagnosis were collated (Table 1). The mean age
of patients was 52.6 ± 13.4 years. All biopsies were
pathologically characterised. Pathological examinations
showed that out of 98 patients, 63 (64.29%) had Squa-
mous Cell Carcinomas (SCC), 4 (4.08%) had Adenocar-
cinomas, 19 (19.39%) had Cervical Interaepithelial
Neoplasia grade I (CIN-I), 4 (4.08%) had CIN-II and 8
(8.16%) of patients had Cervical CIN-III. HPV-DNA was
detected in 78 of 98 patients (79.59%) with cervical spec-
imens using PCR (Table 1). The resulting fragment of
high-risk HPV genotypes 16, 18, 39 and 45 were clarified
effectively using agarose gel electrophoresis. As a stand-
ard procedure, positive and negative controls were in-
cluded for every sample run (Figures 1, 2 and 3). The
most common HPV genotypes detected in this study
were type 18 followed by type 16, 45, and 39. HPV type
16 was present in 23 (29.5%) of cervical specimens,
HPV-18 in 32 (41%) of cervical specimens, HPV-45 in
19 (24.4%) of cervical specimens and HPV-39 in 4 (5.1%)
of cervical specimens.
Our results demonstrated that the most prevalent
HPV genotypes in SCC specimens were HPV-16 and 18,
Adenocarcinoma specimens displayed HPV-16 and 18,
CIN-I specimens displayed HPV types 18, 16, and 45.normalities
notype Total HPV
positive39 45
4 (7.69%) 13 (25%) 52
- - 4
- 2 (14.28%) 14
- - 4
- 4 (100%) 4
4 (5.13%) 19 (24.36%) 78
325
100
Figure 1 Gel electrophoresis pattern of high-risk HPV type 16 by genotype specific primers amplification. M= DNA ladder (100 bp-1000
bp), NC=Negative Control (TE-buffer) (No band), C+h= Internal Control human DNA (723 bp), C+16= Positive Control DNA HPV type 16 (325 bp),
C+31= Positive Control DNA HPV type 31 (520 bp), C+33= Positive Control DNA HPV type 33 (227 bp), C+35= Positive Control DNA HPV type 35
(280 bp), 2 and 4= Positive clinical samples (type 16 (325 bp)), 1 and 3= Negative clinical samples.
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and CIN-III specimens produced HPV-45 (Table 1).
The HPV genotype distribution by age demonstrated
that HPV 16 and HPV 18 were found in all age range of
patients with abnormal cervical biopsies, while that was
not the case for HPV 45 and HPV 39. HPV 45 was the
most prevalent in the 60–69 year age group and was not
found in 20–29 and 70–79 year group respectively. HPV
39 was found in 40–49 and 60–69 years no other age
groups (Table 2).
Discussion
Given the well-established strong relationship between
cervical neoplasia and HPV infection, a high frequency
of oncogenic HPV-DNA in cytologically abnormal biop-
sies is anticipated. Infection by certain types of humanFigure 2 Gel electrophoresis pattern of high-risk HPV type 45 by gen
bp), NC= Negative Control (TE-buffer) (No band), C+h= Positive Control DN
C+39= Positive Control DNA HPV type 39 (340 bp), C+45= Positive Control
(395 bp), 2,3, and 5= Positive clinical samples (type 45 (475 bp)), 1, 4, 6, andpapillomaviruses is recognised as a causal and necessary
factor for cervical cancer [8,9]. Cervical cancer repre-
sents the second most common malignancy among
women around the world and contributes to 9·8% of all
female cancers [1,2].
Histopathological results on 98 cervical biopsies of our
study, revealed that 63 (44%) of abnormal cervical speci-
mens were SCC, 4 (4.1%) were adenocarcinoma, 19
(19.4%) were CIN-I, 4 (4.1%) were CIN-II and 8 (8.2%)
were CIN-III. The results of high-risk HPV typing on
these samples showed that HPV-DNA was found in
56 (83.5%) of cervical carcinoma specimens. This was
reported at a much higher prevalence in Italy (99.3%)
[16], Haifa (98.5%) [17], Norway (92%) [7], Lithuania
(92%) [18], Australia (90%) [19], India (87.8%) [20], and
at an almost similar level in and China (75-83%) [21].475b
100b
otype specific primers amplification. M= DNA ladder (100 bp-1000
A human (723 bp), C+18= Positive Control DNA HPV type 18 (425 bp),
DNA HPV type 45 (475 bp), C+59= Positive Control DNA HPV type 59
7= Negative clinical samples.
3M 541M 2
425bp
100bp
100bp
340bp
Figure 3 Gel electrophoresis patterns of high-risk HPV18 and HPV39 genotypes by genotype specific primers amplification. M= DNA
ladder (100 bp), 1 is positive control type 18 (425 bp), 2 is positive clinical samples type18 (425 bp), 3 is positive control type 39 (340 bp), 4 is
positive clinical samples type39 (340 bp) and 5 is negative clinical samples.
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prevalence of 36% [22].
The main HPV types detected in our study are HPV
18 in 32 (41%), HPV 16 in 23 (29.5%), HPV 45 in 19
(24.4%) and HPV 39 in 4 (5.1%) of the HPV positive
cases. Worldwide, approximately 70% of women diag-
nosed with cervical cancer are found to carry HPV
type16 and HPV type18 [23,24]. This relates positively to
our overall detection of HPV type 16 (28.35%) and 18
(29.85%) in HPV positive cases of patients with cervical
carcinomas.
The geographical variations in HPV distributions may
be due to the difference in the number of samples in
each study and also the cultural attributes in some coun-
tries. Establishment of distinctive religious and cultural
limitations on having multiple sexual partners in coun-
tries like Iran can prevent people from being involved in
risky sexual contacts, which consequently can lower theTable 2 Distribution of HPV genotype according to age
group of patient
Age
groups
HPV genotype Total
HPV
positive
45 18 39 16
20-29 2 (50%) 2 (50%) - - 4
30-39 2 (25%) 4 (50%) - 2 (25%) 8
40-49 4 (19.05%) 11 (52.38%) 2 (9.52%) 4 (19.05%) 21
50-59 7 (35%) 9 (45%) - 4 (20%) 20
60-69 2 (13.33%) 2 (13.33%) 2 (13.33%) 9 (60%) 15
70-79 6 (60%) 4 (40%) - - 10
Total 23 (29.49%) 32 (41.03%) 4 (5.13%) 19 (24.36%) 78risk of HPV infection. On the other hand, limited aware-
ness of Iranian women with respect to HPV and its
implication in cervical cancer aetiology, and also lack of
educational programmes on HPV can be the reasons for
79.59% of HPV genital infection reported in this study.
Previous investigations in different parts of Iran
[25-27] demonstrated HPV type 16 as the main onco-
genic type of HPV associated with cervical cancer while
HPV types 18, 33, 45, 31 and 52 were reported at lower
percentage in patients with cervical cancer.
This is in contrast with our findings that highlight
HPV type 18 (29.85%) and HPV types 16 (28.35%) as the
most prevalent type detected from HPV positive cases
and HPV types 45 (19.4%) and 39 (6%) being found to a
lesser extent in our cervical carcinoma group. This may
be attributable to geographical variation in different
parts of Iran that needs to be investigated further.
In comparison to previous studies in Iran, this study
has provided more detailed information on the pattern
of the relative prevalence of high risk HPV infections in
low and high grade cervical lesions by age. HPV types
16 and 18 were found in all age groups. This can be a
characteristic feature of the population where HPV
transmission continues into middle age and may con-
tribute to cervical cancer incidence. Women in this
population may also have decreased ability to clear HPV
infections, possibly due to age-related reduced immune
responses.
Our results also showed that the prevalence of HPVs
were peaked among women with SCC and fell with de-
creasing grade lesions to CINs. This observation is
consistent with other reports, which highlighted the
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rates of HPV prevalence in other histological classifica-
tions [28,29].
Even though a significant HPV positivity was expected
in all cervical samples, our results show there was a
contrast in the percentage of HPV detected CIN3 (50%)
and SCC (82.5%) compared to other cervical sample
types, where the HPV detection rate was 100%. There
may be a number of reasons for this, such as sample size
and the time length individual samples may have been
stored in paraffin before testing occurred. To account
for any differences in the sample storage, extremely sen-
sitive HPV detection methods were administered and
therefore the results are reflective of what was found
using these sensitive methods.
In summary, an important strength of this study is
that in addition to detection of the most common types
of cervical cancer related HPV (type 16 and 18), we have
detected other high risk types of HPV DNA, 39 and 45,
in samples collected from women with cervical lesions.
This, in line with other studies on the prevalence of
HPV genotypes in cervical cancer, provides a baseline to
assess the impact of current HPV vaccination.Conclusions
The presence of HPV genotypes 16 and 18 in 58.2% cer-
vical cancer in this study will strongly support the imple-
mentation of current vaccination against HPV infection
(aimed to prevent HPV 16 and 18) in north part of Iran.
However, since the protection induced by the current
vaccines is predominately type specific, the identification
of HPV45 and HPV 39 genotypes in this study can be
good evidence for generating a new broad spectrum
prophylactic vaccine that can prevent greater than 56%
of cervical cancers.
There may still be other genotypes of HPV that can
be detected in different geographical areas. Therefore,
further investigation on HPV genotyping in the wider
population would be required.
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